GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Clinical trial NCT00712673 · COMPLETED

Trial details

NCT number: NCT00712673
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Diabetes Mellitus, Type 2

Start date: 2008-06-01
Primary completion: 2011-03-01
Enrollment: 680

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.